Faculty Opinions recommendation of Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
2015 ◽
Vol 16
(3)
◽
pp. 257-265
◽
2020 ◽
Vol 85
(4)
◽
pp. 761-771
◽
2019 ◽
Vol 14
(9)
◽
pp. 1608-1618
◽
2019 ◽